Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA4 | P22748 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | REN | P00797 | 2/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.32 |
| ▸ | USP19 | O94966 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13705383 | 0.94 | CA1 (0.34) | CA1CA2CA4CA9DPP4 | |
| SCHEMBL4291146 | 0.91 | DPP4 (0.41) | CA1CA2CA4CA9DPP4 | |
| SCHEMBL4283733 | 0.90 | CA1 (0.44) | CA1CA2CA4CA9DPP4 | |
| SCHEMBL4296474 | 0.90 | CA1 (0.44) | CA1CA2CA4CA9DPP4 | |
| SCHEMBL4289518 | 0.90 | CA1 (0.44) | CA1CA2CA4CA9DPP4 | |
| SCHEMBL4283871 | 0.90 | CA1 (0.44) | CA1CA2CA4CA9DPP4 | |
| SCHEMBL4292714 | 0.89 | SLC6A2 (0.35) | CA1CA2CA4CA9DPP4 | |
| SCHEMBL4281927 | 0.88 | CA1 (0.41) | CA1CA2CA4CA9DPP4 | |
| SCHEMBL4287655 | 0.86 | DPP4 (0.41) | CA1CA2CA4CA9DPP4 | |
| SCHEMBL4284834 | 0.85 | CA1 (0.38) | CA1CA2CA4CA9DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | CA1 2275/4885CA2 218/4885CA4 296/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | CA1 2275/4885CA2 218/4885CA4 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.